RCS - Imophoron Limited - Imophoron appoints Richard Bungay as CEO

Neurocrine BiosciencesAnnouncement

14/11/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221114:nRSN2218Ga&default-theme=true

RNS Number : 2218G  Imophoron Limited  14 November 2022

Imophoron appoints Richard Bungay as Chief Executive Officer with Founding CEO
Fred Garzoni to become Chief Scientific Officer

 

Richard brings over 25 years of industry experience to lead with Fred the
advancement of the Company's ADDomer™ vaccine candidates into clinical
development and the expansion of the technology platform

 

BRISTOL, UK - 14 November 2022 - Imophoron, a biopharmaceutical company
developing novel, next generation nanoparticle products using its ADDomer™
platform, today announced the appointment of Richard Bungay as Chief Executive
Officer, to be based at the Company's Bristol facility. Richard succeeds
Imophoron's founding CEO, Fred Garzoni, who becomes Chief Scientific Officer,
focused on driving the development of the pipeline and product candidates and
expansion of the ADDomer™ platform.

 

"Richard joins us at a critical stage of Imophoron's development, as we
prepare to rapidly progress our lead vaccine candidate for respiratory
syncytial virus through IND-enabling studies to the clinic, and further expand
the utility of the novel, thermostable, nanoparticle ADDomer™ platform,"
said Damian Marron, Chairman of the Board of Imophoron. "We believe Richard's
extensive experience across all phases of development of novel products along
with his exceptional leadership skills will enable Imophoron to realise the
full promise of its ADDomer™ platform."

 

Richard was formerly Chief Executive Officer of AIM-listed Diurnal Group plc,
where he led the recent sale of the company to Neurocrine Biosciences. Richard
has over 25 years' experience in senior roles in the biotechnology and
pharmaceutical sectors, including as CFO and COO at Mereo Biopharma and CEO of
Chroma Therapeutics. Richard has been involved in fundraisings totalling over
$250 million, along with the negotiation and execution of multiple business
development deals. Richard also has extensive experience of taking novel drugs
from research through to clinical development and commercialisation and has
been involved with the development of six currently marketed drugs, including
three novel biological agents. Richard is a Chartered Accountant and has a
First Class degree in Chemistry from Nottingham University.

 

"I have been hugely impressed at the potential of the ADDomer™ platform to
deliver a step-change for vaccines, as well as potential for its expansion
into other areas," commented Richard Bungay. "I am delighted to be joining the
highly skilled team at Imophoron at this pivotal stage of the Company's
development and to work with Fred as we prepare to progress our pipeline from
research into clinical proof-of-concept activities. "

 

Fred Garzoni, Co-Founder and CSO, commented: "I am excited to welcome Richard
to the Company, and I am looking forward to working alongside him as we enter
a new phase of the Company's development. In particular, his experience of
financing and business development will be crucial as we seek to build on the
excellent achievements of our team."

 

 

For further information, please visit www.imophoron.com or contact:

Richard Bungay, Chief Executive Officer

contact@imophoron.com

 

 

About Imophoron

Imophoron was founded in 2017 and is based at Science Creates in Bristol, UK.
Imophoron has developed a novel next-generation nanoparticle platform,
ADDomer™, initially focused on the development of vaccines to combat present
and future infectious diseases, including 'Disease X' outbreaks. ADDomer™
has demonstrated both thermostability and the ability to deliver vaccines
intranasally which is expected to provide enhanced immunoprotection. These
attributed highlight ADDomer's potential for the creation of the next
generation of vaccine candidates.

 

The ADDomer™ platform is based on a self-assembling thermotolerant protein
that permits rapid insertion of large numbers of peptide and protein epitopes
in a single particle. The Company has already generated ADDomer™ vaccines
candidates for respiratory syncytial virus (RSV), chikungunya and COVID-19.
The ADDomer™ platform also has significant potential to generate therapeutic
candidates to treat diseases with high unmet needs such as oncology.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZMMMNFLGZZM